Technical Data
17-AAG (17-allylamino-17-demethoxygeldanamycin, Telatinib, Tanespimycin, NSC-330507, CNF-101, KOS-953, GLD-36, CP 127374)
Biochemicals Storage: -20CShipping: Blue Ice
Semi-synthetic derivative of geldanamycin, demonstrating greater stability and lower in vivo toxicity than its parent compound. 17-AAG binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin, but the binding is weaker.

Soluble in DMSO at 150mg/ml; soluble in ethanol at 5mg/ml; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50uM; buffers, serum, or other additives may increase or decrease the aqueous solubility.

Storage and Stability:
May be stored at RT for short-term only. Long-term storage is recommended at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

CAS Number:

Molecular Formula:

Molecular Weight:
Purity: ~99%
Form: Supplied as a purple powder.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Schulte, T.W. and Neckers, L.M. "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin." Cancer Chemother. Pharmacol. 42:273-279 (1998). 2. Basso, A.D., et al. "Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2." Oncogene 21:1159-1166 (2002). 3. Kamal, A., et al. "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors." Nature 425:407-10 (2003). 4. Nguyen, D.M., et al. "Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin." J. Thorac. Cardiovasc. Surg. 118:908-915 (1999) 5. Solit, D.B., et al. "Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol." Cancer Res. 63:2139-2144 (2003). 6. Vasilevskaya, I.A., et al. "Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines." Mol Pharmacol. 65:235-243 (2004). 7. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10:4813-4821 (2004).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.